Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larotrectinib - Bayer/Loxo Oncology

Drug Profile

Larotrectinib - Bayer/Loxo Oncology

Alternative Names: ARRY-470; BAY 2757556; Larotrectinib sulfate - Bayer/Loxo Oncology; LOXO 101; VITRAKVI

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Bayer; Loxo Oncology; National Cancer Institute (USA)
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Solid tumours
  • Phase II Histiocytosis; Non-Hodgkin's lymphoma
  • Phase I/II CNS cancer
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Oct 2023 Updated pooled efficacy and adverse events data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Jun 2023 Updated efficacy and adverse events data from the phase II trial in NAVIGATE presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
  • 02 Jun 2023 Updated pooled efficacy data from the phase II NAVIGATE, phase I/II SCOUT and a phase I trial in Solid tumour presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top